TriSalus Life Sciences, Inc. is dedicated to improving outcomes for patients with liver and pancreatic tumors and is studying therapeutic regimens aimed at accomplishing this commitment. Regulatory requirements associated with the development of new therapies mandate that TriSalus demonstrate the new therapeutic or regimen meets health authority (HA) standards of safety and effectiveness. This is done through gathering outcome data from clinical trials and submitting these results to HAs for evaluation and approval or licensing. Clinical trials are the best mechanism for efficiently getting a new therapeutic to the most patients in a population with an unmet medical need.
TriSalus recognizes that there are patients with serious or life-threatening conditions that are ineligible or are unable to participate in one of our clinical trials who may potentially benefit from a TriSalus investigational therapeutic. Requests for access for these patients are commonly referred to as a request for “Early Access” or “Compassionate Use” or a therapy issued on a “Named Patient” basis, depending on the HA/jurisdiction. These patients often have no remaining treatment options and do not qualify for any appropriate clinical trial. Under these circumstances, TriSalus welcomes a patient’s physician to submit a request for pre-approval access to the therapeutic.1
For TriSalus to consider an early access request, the following criteria must be met:
A patient with interest in obtaining access to a TriSalus investigational drug should discuss their eligibility for a TriSalus clinical trial with their physician or health care provider. Information about our company’s clinical trials may be obtained here.
If the physician does not believe that the patient is eligible for a clinical trial, there are no other options available to patient, and the physician believes the investigational therapeutic may be appropriate for the patient, the physician should contact TriSalus to make a request on the patient’s behalf. Physicians seeking to discuss access with TriSalus may contact TriSalus at email@example.com.
It is important to remember that without a regulatory approval, possible safety risks and benefits for the investigational therapy have not been established. Therefore, patients and physicians should consider all possible safety risks and benefits when seeking access to an investigational drug.
The federal Right to Try Act was signed into law on May 30, 2018, by former President Trump (now codified as section 561B of the Federal Food, Drug and Cosmetic Act, 21 USC 360bbb(b)). TriSalus believes that its Early Access to Investigational Products Policy fulfills the mandates of this act.
TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.
Thank you for visiting our site.